DNA repair mutations (BRCA1 and BRCA2) are found in metastatic castration-resistant prostate cancer (CRPC) patients. Here, we report a case of a 71-year-old male patient with metastatic CRPC along with BRCA2 and PTEN mutations.
As per the genomic findings of the Foundation One report, FDA-approved therapies were available for other tumor types, such as olaparib for the loss of BRCA2 and everolimus for the loss of PTEN exons 2-9. These findings were confirmed in another novel phenotypic assay that revealed the sensitivity of olaparib and carboplatin combination therapy. After 4 cycles, our patient achieved a partial response along with a good performance status.
Case reports in oncology. 2020 Feb 04*** epublish ***
Pramod Kumar Julka, Amit Verma, Kush Gupta
Max Institute of Cancer Care, New Delhi, India., Catalyst Clinical Services Pvt. Ltd., New Delhi, India.